REFERENCES
1. Toh MR, Wong EYT, Wong SH, et al. Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology. 2023;164:766-82.
2. Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20:864-84.
3. Koshy A. Evolving global etiology of hepatocellular carcinoma (HCC): insights and trends for 2024. J Clin Exp Hepatol. 2025;15:102406.
4. Motta BM, Masarone M, Torre P, Persico M. From non-alcoholic steatohepatitis (NASH) to hepatocellular carcinoma (HCC): epidemiology, incidence, predictions, risk factors, and prevention. Cancers. 2023;15:5458.
5. De Vos WM, Tilg H, Van Hul M, Cani PD. Gut microbiome and health: mechanistic insights. Gut. 2022;71:1020-32.
6. Schneider KM, Mohs A, Gui W, et al. Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment. Nat Commun. 2022;13:3964.
7. Hsu CL, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease. Nat Rev Microbiol. 2023;21:719-33.
8. Kim Y, Kim G, Kim S, et al. Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor. Cell Host Microbe. 2024;32:1380-93.e9.
9. Huang DQ, El-serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2020;18:223-38.
10. Han H, Jiang Y, Wang M, et al. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis. Crit Rev Food Sci Nutr. 2021;63:1689-706.
11. Song Q, Zhang X. The role of gut-liver axis in gut microbiome dysbiosis associated NAFLD and NAFLD-HCC. Biomedicines. 2022;10:524.
12. Zhou Y, Wang M, Wang Z, et al. Polysaccharides from hawthorn fruit alleviate high-fat diet-induced NAFLD in mice by improving gut microbiota dysbiosis and hepatic metabolic disorder. Phytomedicine. 2025;139:156458.
13. Zhao H, Li Y, Liu N, et al. Ganoderma lucidum polysaccharides alleviate non-alcoholic fatty liver disease by modulating gut microbiota against TLR4/NF-κB/MAPK pathway and activating AMPK pathway. J Ethnopharmacol. 2026;355:120723.
14. Wang S, Sheng F, Zou L, Xiao J, Li P. Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism. J Adv Res. 2021;34:109-22.
15. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184:2537-64.
16. Clifford BL, Sedgeman LR, Williams KJ, et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metab. 2021;33:1671-84.e4.
17. Åberg F, Jiang ZG, Cortez-pinto H, Männistö V. Alcohol-associated liver disease - Global epidemiology. Hepatology. 2024;80:1307-22.
18. Hong X, Huang S, Jiang H, et al. Alcohol-related liver disease (ALD): current perspectives on pathogenesis, therapeutic strategies, and animal models. Front Pharmacol. 2024;15:1432480.
19. Hyun J, Han J, Lee C, Yoon M, Jung Y. Pathophysiological aspects of alcohol metabolism in the liver. Int J Mol Sci. 2021;22:5717.
20. Wu X, Fan X, Miyata T, et al. Recent advances in understanding of pathogenesis of alcohol-associated liver disease. Annu Rev Pathol. 2023;18:411-38.
21. Yang A, Inamine T, Hochrath K, et al. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Investig. 2017;127:2829-41.
22. Zuo S, Ma J, Li X, et al. The dual role of gut microbiota and their metabolites in hepatocellular carcinoma: a context-dependent framework. Microorganisms. 2025;14:73.
23. Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases. Cell Mol Immunol. 2020;18:4-17.
24. Cheng Z, Yang L, Chu H. The role of gut microbiota, exosomes, and their interaction in the pathogenesis of ALD. J Adv Res. 2025;72:353-67.
25. Duan Y, Llorente C, Lang S, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 2019;575:505-11.
26. Odenwald MA, Paul S. Viral hepatitis: past, present, and future. World J Gastroenterol. 2022;28:1405-29.
27. Tian Z, Xu C, Yang P, et al. Molecular pathogenesis: connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma. Front Immunol. 2022;13:984728.
28. Raziq K, Shah SQA, Shahzad MN, Ummara UE, Subhan M, Nazir MM. The gut-liver-virus axis in hepatitis B and C: microbiota, immunometabolism, and exosome-mediated therapeutic opportunities. Naunyn Schmiedebergs Arch Pharmacol. 2025;399:6221-37.
29. Yan F, Zhang Q, Shi K, et al. Gut microbiota dysbiosis with hepatitis B virus liver disease and association with immune response. Front Cell Infect Microbiol. 2023;13:1152987.
30. Yuan H, Xu R, Li S, et al. The malignant transformation of viral hepatitis to hepatocellular carcinoma: mechanisms and interventions. MedComm. 2025;6:e70121.
31. Shen Y, Wu S, Chen Y, et al. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response. Gut Microbes. 2022;15:2155018.
32. Martin-gallausiaux C, Marinelli L, Blottière HM, Larraufie P, Lapaque N. SCFA: mechanisms and functional importance in the gut. Proc Nutr Soc. 2020;80:37-49.
33. Zhang M, Huang X, Zhang Y, et al. Gut microbial metabolite butyrate suppresses hepatocellular carcinoma growth via CXCL11-dependent enhancement of natural killer cell infiltration. Gut Microbes. 2025;17:2519706.
34. Song Q, Zhang X, Liu W, et al. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma. J Hepatol. 2023;79:1352-65.
35. Fusco W, Lorenzo MB, Cintoni M, et al. Short-chain fatty-acid-producing bacteria: key components of the human gut microbiota. Nutrients. 2023;15:2211.
36. Mcbrearty N, Arzumanyan A, Bichenkov E, Merali S, Merali C, Feitelson M. Short chain fatty acids delay the development of hepatocellular carcinoma in HBx transgenic mice. Neoplasia. 2021;23:529-38.
37. Guo X, Okpara ES, Hu W, et al. Interactive relationships between intestinal flora and bile acids. Int J Mol Sci. 2022;23:8343.
38. Shen R, Ke L, Li Q, et al. Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma. Hepatol Int. 2022;16:396-411.
39. Liu Y, Zhu J, Jin Y, et al. Disrupting bile acid metabolism by suppressing Fxr causes hepatocellular carcinoma induced by YAP activation. Nat Commun. 2025;16:3583.
40. Saha B, Banerjee A, Pathak R, Duttaroy AK, Pathak S. Trimethylamine N-Oxide (TMAO) and cancer risk: insights into a possible link. Biomed Pharmacother. 2025;192:118592.
41. Wu Y, Rong X, Pan M, et al. Integrated analysis reveals the gut microbial metabolite TMAO promotes inflammatory hepatocellular carcinoma by upregulating POSTN. Front Cell Dev Biol. 2022;10:840171.
42. Pabst O, Hornef MW, Schaap FG, Cerovic V, Clavel T, Bruns T. Gut-liver axis: barriers and functional circuits. Nat Rev Gastroenterol Hepatol. 2023;20:447-61.
43. Liu J, Wu A, Cai J, She Z, Li H. The contribution of the gut-liver axis to the immune signaling pathway of NAFLD. Front Immunol. 2022;13:968799.
44. Xu Y, Fang F, Jiao H, et al. Activated hepatic stellate cells regulate MDSC migration through the SDF-1/CXCR4 axis in an orthotopic mouse model of hepatocellular carcinoma. Cancer Immunol Immunother. 2019;68:1959-69.
45. Li C, Cai C, Wang C, Chen X, Zhang B, Huang Z. Gut microbiota-mediated gut-liver axis: a breakthrough point for understanding and treating liver cancer. Clin Mol Hepatol. 2025;31:350-81.
46. Tilg H, Adolph TE, Trauner M. Gut-liver axis: pathophysiological concepts and clinical implications. Cell Metab. 2022;34:1700-18.
47. Yoon SJ, Han SK, Kim TS, et al. The crosstalk between gut microbiota and microbiota-derived metabolites in hepatocellular carcinoma. Crit Rev Microbiol. 2025;51:1315-29.
48. Zhou A, Tang L, Zeng S, Lei Y, Yang S, Tang B. Gut microbiota: a new piece in understanding hepatocarcinogenesis. Cancer Lett. 2020;474:15-22.
49. Machida K, Tahara SM. Immunotherapy and microbiota for targeting of liver tumor-initiating stem-like cells. Cancers. 2022;14:2381.
50. Zhra M, Elahi MA, Tariq A, Abu-zaid A, Yaqinuddin A. Sirtuins and gut microbiota: dynamics in health and a journey from metabolic dysfunction to hepatocellular carcinoma. Cells. 2025;14:466.
51. Chen P, Yang C, Ren K, et al. Modulation of gut microbiota by probiotics to improve the efficacy of immunotherapy in hepatocellular carcinoma. Front Immunol. 2024;15:1504948.
52. Scarpellini E, Scarlata GGM, Santori V, Scarcella M, Kobyliak N, Abenavoli L. Gut microbiota, deranged immunity, and hepatocellular carcinoma. Biomedicines. 2024;12:1797.
53. Huo R, Xu Q, You Y, et al. Bifidobacterium boosts anti-PD-1 effectiveness through JAK pathway in hepatocellular carcinoma. npj Precis Onc. 2025;9:251.
54. Temraz S, Nassar F, Kreidieh F, Mukherji D, Shamseddine A, Nasr R. Hepatocellular carcinoma immunotherapy and the potential influence of gut microbiome. Int J Mol Sci. 2021;22:7800.
55. Liu X, Li S, Wang L, Ma K. Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment. Biochim Biophys Acta Mol Basis Dis. 2024;1870:167230.
56. Huang M, Ji Q, Huang H, Wang X, Wang L. Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification. Gut Microbes. 2025;17:2486519.
57. Cheng A, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862-73.
58. Abou-alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1:EVIDoa2100070.
59. Zhu C, Zhang C, Wang S, et al. Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma. J Immunother Cancer. 2024;12:e008686.
60. Zhang F, Lo EKK, Chen C, et al. Probiotics mixture, prohep: a potential adjuvant for low-dose sorafenib in metabolic dysfunction-associated steatotic liver disease-associated hepatocellular carcinoma suppression through modulating gut microbiota. Probiotics Antimicrob Proteins. 2025;18:956-72.
61. Kumar M, Kaur R, Kanthaje S, Dhiman RK, Chakraborti A. Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2022;149:5823-39.
62. Yu Y, Shen X, Xiao X, Li L, Huang Y. Butyrate modification promotes intestinal absorption and hepatic cancer cells targeting of ferroptosis inducer loaded nanoparticle for enhanced hepatocellular carcinoma therapy. Small. 2023;19:e2301149.
63. Yu H, Lin G, Jiang J, et al. Synergistic activity of Enterococcus Faecium-induced ferroptosis via expansion of IFN-γ+CD8+ T cell population in advanced hepatocellular carcinoma treated with sorafenib. Gut Microbes. 2024;16:2410474.
64. Bian C, Wang Y, Yu A, et al. Gut microbiota changes and biological mechanism in hepatocellular carcinoma after transarterial chemoembolization treatment. Front Oncol. 2022;12:1002589.
65. Li R, Liu J, Ye F, et al. Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC. J Hepatol. 2026;84:808-22.
66. Zhang J, Cheng Y, Wei J, et al. Transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors versus tyrosine kinase inhibitors plus immune checkpoint inhibitors in unresectable hepatocellular carcinoma with first- or lower-order portal vein tumor thrombosis. Cardiovasc Intervent Radiol. 2024;47:751-61.
67. Liu B, Wan S, Zhang Y, et al. Gut microbiome remodeling across hepatocellular carcinoma progression and transarterial chemoembolization is associated with therapeutic response and prognosis. Clin Exp Med. 2026;26:222.
68. Luo W, Guo S, Zhou Y, et al. Hepatocellular carcinoma: how the gut microbiota contributes to pathogenesis, diagnosis, and therapy. Front Microbiol. 2022;13:873160.
69. Yang J, He Q, Lu F, et al. A distinct microbiota signature precedes the clinical diagnosis of hepatocellular carcinoma. Gut Microbes. 2023;15:2201159.
70. Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2019;68:1014-23.
71. Li X, Yi Y, Wu T, et al. Integrated microbiome and metabolome analysis reveals the interaction between intestinal flora and serum metabolites as potential biomarkers in hepatocellular carcinoma patients. Front Cell Infect Microbiol. 2023;13:1170748.
72. Zheng C, Lu F, Chen B, et al. Gut microbiome as a biomarker for predicting early recurrence ofHBV‐related hepatocellular carcinoma. Cancer Sci. 2023;114:4717-31.
73. Chuanbing Z, Zhengle Z, Ruili D, Kongfan Z, Jing T. Genes modulating butyrate metabolism for assessing clinical prognosis and responses to systematic therapies in hepatocellular carcinoma. Biomolecules. 2022;13:52.
74. Feng Y, Han M, Zhou Y, et al. The multifaceted role of microbiota in liver cancer: pathogenesis, therapy, prognosis, and immunotherapy. Front Immunol. 2025;16:1575963.
75. Chen P, Devkota S, Shiao S, Hendifar A, Yang JD. Gut microbiome, a novel precision medicine biomarker for hepatocellular carcinoma. Front Immunol. 2025;16:1568962.
76. Zhang Y, Liu W, Wong CC, et al. Catenibacterium mitsuokai promotes hepatocellular carcinogenesis by binding to hepatocytes and generating quinolinic acid. Cell Metab. 2025;37:1998-2013.e7.
77. Xin Y, Peng G, Song W, Zhou X, Huang X, Cao X. Gut microbiota as a prognostic biomarker for unresectable hepatocellular carcinoma treated with anti-PD-1 therapy. Front Genet. 2024;15:1366131.
78. Zhang M, Liu J, Xia Q. Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target. Exp Hematol Oncol. 2023;12:84.
79. Zhao Y, Gong C, Xu J, et al. Research progress of fecal microbiota transplantation in liver diseases. JCM. 2023;12:1683.
80. Lu Y, Yuan X, Wang M, et al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. J Hematol Oncol. 2022;15:47.
81. Abenavoli L, Maurizi V, Rinninella E, et al. Fecal microbiota transplantation in NAFLD treatment. Medicina. 2022;58:1559.
82. Xue L, Deng Z, Luo W, He X, Chen Y. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial. Front Cell Infect Microbiol. 2022;12:759306.
83. Thilakarathna WPW, Rupasinghe HV, Ridgway ND. Mechanisms by which probiotic bacteria attenuate the risk of hepatocellular carcinoma. Int J Mol Sci. 2021;22:2606.
84. Yan Z, Han C, Jia J, et al. The landscape of gut microbiota in hepatocarcinogenesis: a comprehensive review of pathogenesis and therapeutic interventions. Int J Surg. 2026;112:1673-95.
85. Lau HC, Zhang X, Ji F, et al. Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid. eBioMedicine. 2024;100:104952.
86. Goyal H, Fatima K, Kaur J. Understanding crosstalk between the gut and liver microbiome: pathogenesis to therapeutic approaches in liver cancer. Cancer Cell Int. 2025;25:291.
87. Matray C, Debras C, Chatziioannou AC, Perlemuter G, Jenab M, Voican CS. Diet habits and hepatocellular carcinoma - potential implication for clinical practice. Nutr Rev. 2025;83:2372-88.
88. George ES, Sood S, Broughton A, et al. The association between diet and hepatocellular carcinoma: a systematic review. Nutrients. 2021;13:172.
89. Zhang X, Coker OO, Chu ES, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut. 2021;70:761-74.
90. Ran X, Hu G, He F, et al. Phytic acid improves hepatic steatosis, inflammation, and oxidative stress in high-fat diet (HFD)-fed mice by modulating the gut-liver axis. J Agric Food Chem. 2022;70:11401-11.
91. Cramer T. Impact of dietary carbohydrate restriction on the pathobiology of hepatocellular carcinoma: the gut-liver axis and beyond. Semin Immunol. 2023;66:101736.
92. Shen X, Zhao D, Wang F, et al. Dietary intervention reshapes gut microbiota and lipid metabolism to enhance anti-tumor immunity and prognosis in hepatocellular carcinoma: a randomized controlled trial. BMC Cancer. 2026;26:42.
93. Vallianou N, Christodoulatos GS, Karampela I, et al. Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives. Biomolecules. 2021;12:56.
94. Song Y, Lau HC, Zhang X, Yu J. Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma. Cancer Biol Med. 2023;21:144-62.
95. Cao L, Xie Y, Fleishman JS, Liu X, Chen Z. Hepatocellular carcinoma and lipid metabolism: Novel targets and therapeutic strategies. Cancer Lett. 2024;597:217061.
96. Ooi VY, Yeh T. Recent advances and mechanisms of phage-based therapies in cancer treatment. Int J Mol Sci. 2024;25:9938.
97. Hsu CL, Duan Y, Fouts DE, Schnabl B. Intestinal virome and therapeutic potential of bacteriophages in liver disease. J Hepatol. 2021;75:1465-75.
98. Gan L, Feng Y, Du B, et al. Bacteriophage targeting microbiota alleviates non-alcoholic fatty liver disease induced by high alcohol-producing Klebsiella pneumoniae. Nat Commun. 2023;14:3215.
99. Federici S, Kredo-russo S, Valdés-mas R, et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. Cell. 2022;185:2879-98.e24.
100. Saeed H, Díaz LA, Gil-gómez A, et al. Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31:S94-111.
101. Lau HC, Zhang X, Yu J. Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2025;22:619-38.
102. Hajjar R, Mars RAT, Kashyap PC. Harnessing the microbiome for cancer therapy. Nat Rev Microbiol. 2026;24:392-407.
103. Fujiki J, Schnabl B. Phage therapy: targeting intestinal bacterial microbiota for the treatment of liver diseases. JHEP Rep. 2023;5:100909.
104. Muhammad S, Li M, Jia Q, et al. Advances in the engineering of living probiotics for cancer immunotherapy. Theranostics. 2026;16:1164-226.
105. Yi H, Xu H. Novel biomarkers for hepatocellular carcinoma detection and treatment. Hepatobiliary Surg Nutr. 2024;13:901-4.
106. Xiao K, Li K, Xiao K, Yang J, Zhou L. Gut microbiota and hepatocellular carcinoma: metabolic products and immunotherapy modulation. Cancer Med. 2025;14:e70914.
107. Elie C, Perret M, Hage H, et al. Comparison of DNA extraction methods for 16S rRNA gene sequencing in the analysis of the human gut microbiome. Sci Rep. 2023;13:10279.
108. Schnabl B, Damman CJ, Carr RM. Metabolic dysfunction-associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations. J Clin Investig. 2025;135:e186423.
109. Sgamato C, Marchitto SA, Compare D, et al. Gut microbiota-mediated molecular events in hepatocellular carcinoma: from pathogenesis to treatment. Livers. 2026;6:4.
110. Chu H, Duan Y, Lang S, et al. The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. J Hepatol. 2020;72:391-400.
111. Gellert‐kristensen H, Richardson TG, Davey Smith G, Nordestgaard BG, Tybjærg‐hansen A, Stender S. Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population. Hepatology. 2020;72:845-56.
112. Stickel F, Lutz P, Buch S, et al. Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers. Hepatology. 2020;72:88-102.
113. Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020;368:973-80.
